Regorafenib also showed improved disease control rate in patients compared with placebo, although the difference in objective response rate (partial response plus stable disease assessed at least 6 weeks after randomization) between the two arms (1.0% versus 0.4%) did not reach statistical significance.
← all excerpts
Critical appraisal of the use of regorafenib in the management of colorectal cancer.
1
—
—